Ticker >

Piramal Pharma share price

Piramal Pharma Ltd.

NSE: PPLPHARMA BSE: 543635 SECTOR: Pharmaceuticals & Drugs  110k   161   53

276.00
-5.85 (-2.08%)
BSE: 04 Nov 03:33 PM

Price Summary

Today's High

₹ 284.3

Today's Low

₹ 271.35

52 Week High

₹ 284.35

52 Week Low

₹ 99.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

36590.65 Cr.

Enterprise Value

37500.81 Cr.

No. of Shares

132.57 Cr.

P/E

56.93

P/B

5.21

Face Value

₹ 10

Div. Yield

0.04 %

Book Value (TTM)

₹  52.95

CASH

241.73 Cr.

DEBT

1151.89 Cr.

Promoter Holding

34.95 %

EPS (TTM)

₹  4.85

Sales Growth

27.5%

ROE

6.55 %

ROCE

8.33%

Profit Growth

462.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year27.5%
3 Year14.31%
5 YearNA

Profit Growth

1 Year462.91%
3 Year-11.87%
5 YearNA

ROE%

1 Year6.55%
3 Year5.29%

ROCE %

1 Year8.33%
3 Year7.28%

Debt/Equity

0.1723

Price to Cash Flow

102.13

Interest Cover Ratio

5.7397

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 34.95 0.00
Jun 2024 34.95 0.00
Mar 2024 35.02 0.00
Dec 2023 35.02 0.00
Sep 2023 35.02 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.1396120387684.
  • The company has an efficient Cash Conversion Cycle of 5.2636 days.

 Limitations

  • The company has shown a poor profit growth of -11.8677337081194% for the Past 3 years.
  • The company has shown a poor revenue growth of 14.3143409120378% for the Past 3 years.
  • Company has a poor ROE of 5.28586666666667% over the past 3 years.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high PE of 56.93.
  • The company is trading at a high EV/EBITDA of 32.9478.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 994.24 1024.14 1525.3 1063.2 1284.39
Total Expenditure 908.08 898.61 1135.66 911.57 1031.5
Operating Profit 86.16 125.53 389.64 151.63 252.89
Other Income 89.08 33.11 53.19 36.76 106.38
Interest 28.22 17.42 27.66 24.88 29.95
Depreciation 50.83 51.56 52.5 51.85 53.61
Exceptional Items 0 0 0 0 0
Profit Before Tax 96.19 89.66 362.67 111.66 275.71
Tax 19.03 15.32 89.59 26.39 65.65
Profit After Tax 77.16 74.34 273.08 85.27 210.06
Adjusted EPS (Rs) 0.58 0.56 2.06 0.64 1.59

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2938.81 3340.42 3443.22 4390.11
Total Expenditure 2319.88 2865.14 3345.69 3790.71
Operating Profit 618.93 475.28 97.53 599.4
Other Income 197.97 224.79 341.07 220.58
Interest 4.71 57.29 115.87 107.1
Depreciation 143.64 165.37 192.08 205.26
Exceptional Items 18.23 -15.08 -6.96 0
Profit Before Tax 686.78 462.33 123.69 507.62
Tax 115.28 94.79 54.19 116.4
Net Profit 571.5 367.54 69.5 391.22
Adjusted EPS (Rs.) 5.61 3.03 0.57 2.96

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 994.6 1185.91 1193.32 1322.95
Total Reserves 3106.02 3937.21 4068.47 5389.12
Borrowings 0 477.12 592.34 363.94
Other N/C liabilities 184.38 323.6 490.83 495.86
Current liabilities 1566.96 1655.39 1951.29 2307.35
Total Liabilities 5851.96 7579.23 8296.25 9879.22
Assets
Net Block 1626.81 2438.98 2601.87 2612.16
Capital WIP 79.34 157.47 136.5 232.4
Intangible WIP 41.66 247.69 280.07 300.84
Investments 1591.52 1592.52 1646.87 1646.88
Loans & Advances 649.84 963.54 1282.22 1715.86
Other N/C Assets 0 0.04 0.04 0
Current Assets 1862.79 2178.99 2348.68 3371.08
Total Assets 5851.96 7579.23 8296.25 9879.22
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 668.55 477.41 123.69 507.62
Adjustment -310.48 42.92 50.7 221.26
Changes in Assets & Liabilities -228.06 -168.48 -42.84 -292.78
Tax Paid -95.29 -102.66 -60.03 -77.81
Operating Cash Flow 34.72 249.19 71.52 358.29
Investing Cash Flow -4382.89 -1164.62 -435.05 -635.15
Financing Cash Flow 4494.16 896.4 290.12 451.38
Net Cash Flow 145.99 -19.03 -73.41 174.52

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 35.02 35.02 35.02 34.95 34.95
aasan corporate solutions... 0.68 0.68 0.68 0.67 0.67
anand piramal trust 0.05 0.05 0.05 0.05 0.05
master dev piramal deyoun... 0.01 0.01 0.01 0.01 0.01
mr. ajay g. piramal 0.04 0.04 0.04 0.04 0.04
mr. anand piramal 0.07 0.07 0.07 0.07 0.07
mr. peter deyoung 0.03 0.03 0.03 0.03 0.03
ms. anya piramal deyoung 0.01 0.01 0.01 0.01 0.01
ms. nandini piramal 0.02 0.02 0.02 0.02 0.02
nandini piramal trust 0.04 0.04 0.04 0.04 0.04
piramal welfare trust (fo... 0.80 0.80 0.80 0.80 0.80
prl realtors llp 3.01 3.01 3.01 3.00 3.00
the ajay g. piramal found... 0.33 0.33 0.33 0.33 0.33
the sri krishna trust thr... 26.67 26.67 26.67 26.62 26.62
v3 designs llp 3.25 3.25 3.25 3.25 3.25
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 64.98 64.98 64.98 65.05 65.05
ca alchemy investments 18.04 18.04 18.04 18.00 18.00
east bridge capital maste... 2.17 4.71 4.35 4.35 3.27
hdfc trustee company limi... - - 5.01 6.66 7.13
indiahold limited 1.31 1.31 1.31 1.30 1.30
investor education and pr... 0.24 - 0.24 0.24 0.24
life insurance corporatio... 3.49 2.05 1.85 1.84 1.62
llp 0.98 0.99 0.92 0.87 0.80
icici prudential value di... 2.16 1.31 1.22 - -
college retirement equiti... 1.58 1.20 - - -
hdfc mutual fund - hdfc f... - 1.80 - - -
investor education and pr... - 0.24 - - -
east bridge capital maste... 2.74 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Piramal Pharma reports over 4-fold jump in Q2 consolidated net profit24 Oct 2024, 11:30AM Piramal Pharma - Quaterly Results23 Oct 2024, 8:07PM Piramal Pharma - Quaterly Results23 Oct 2024, 8:07PM Piramal Pharma’s PPS business to invest $80 million to expand Kentucky facility1 Oct 2024, 11:58AM Piramal Pharma gets SBTi approval for GHG Commitment17 Sep 2024, 10:57AM Piramal Pharma informs about disclosure 10 Sep 2024, 5:36PM Piramal Pharma to subscribe preference shares in arm against outstanding loan30 Aug 2024, 11:44AM Piramal Pharma informs about disclosure 31 Jul 2024, 2:51PM Piramal Pharma gets nod to sell unit in Thane31 Jul 2024, 2:11PM Piramal Pharma reports consolidated net loss of Rs 88.64 crore in Q1 27 Jul 2024, 3:00PM Piramal Pharma - Quaterly Results26 Jul 2024, 12:41PM Piramal Pharma - Quaterly Results26 Jul 2024, 12:41PM Piramal Pharma - Quaterly Results26 Jul 2024, 12:41PM Piramal Pharma informs about grant of stock options 26 Jul 2024, 11:04AM USFDA completes inspection at Piramal Pharma’s PPDS Ahmedabad facility13 Jul 2024, 11:01AM Piramal Pharma submits BRSR 2 Jul 2024, 5:31PM Piramal Pharma informs about AGM and annual report 2 Jul 2024, 5:19PM Piramal Pharma informs about analyst meet4 Jun 2024, 4:51PM Piramal Pharma informs about disclosures 31 May 2024, 5:20PM Piramal Pharma informs about disclosure 23 May 2024, 11:36AM Piramal Pharma reports 2- fold jump in Q4 consolidated net profit13 May 2024, 11:41AM Piramal Pharma - Quaterly Results10 May 2024, 8:31PM Piramal Pharma - Quaterly Results10 May 2024, 8:31PM Piramal Pharma’s consumer products division launches new digital campaign for 'Polycrol’7 May 2024, 4:12PM Piramal Pharma informs about disclosure27 Apr 2024, 2:48PM Piramal Pharma’s consumer products division forays into men's grooming segment11 Apr 2024, 4:31PM Piramal Pharma informs about disclosure 18 Mar 2024, 3:18PM USFDA conducts PAI inspection at Piramal Pharma’s USA facility 24 Feb 2024, 3:09PM Piramal Pharma informs about disclosure24 Feb 2024, 2:29PM Piramal Pharma submits analyst meet intimation21 Feb 2024, 4:58PM USFDA conducts PAI inspection at Piramal Pharma’s USA facility7 Feb 2024, 6:20PM Piramal Pharma - Quaterly Results30 Jan 2024, 8:48PM Piramal Pharma - Quaterly Results30 Jan 2024, 8:48PM Piramal Pharma’s division launches new concentration of Zinc Sulfate for Injection in U.S.17 Jan 2024, 9:21AM Piramal Pharma gets EIR for manufacturing facility in USA9 Nov 2023, 12:58PM Piramal Pharma - Quaterly Results27 Oct 2023, 10:15PM Piramal Pharma - Quaterly Results27 Oct 2023, 10:15PM Piramal Pharma informs about conference call with investor18 Oct 2023, 5:11PM Piramal Pharma’s PPS business launches high-throughput screening facility16 Oct 2023, 6:35PM USFDA conducts GMP Inspection at Piramal Pharma’s Bethlehem facility29 Sep 2023, 12:16PM Piramal Pharma informs about disclosure 12 Sep 2023, 5:17PM Piramal Pharma informs about sustainability report 8 Sep 2023, 2:21PM Piramal Pharma informs about newspaper advertisement24 Aug 2023, 5:04PM Piramal Pharma - Quaterly Results3 Aug 2023, 9:06PM Piramal Pharma - Quaterly Results3 Aug 2023, 9:06PM Piramal Pharma gets Sebi's nod to raise up to Rs 1,050 crore through rights issue of shares18 Jul 2023, 4:00PM Piramal Pharma informs about press release 6 Jun 2023, 5:01PM Piramal Pharma informs about disclosure1 Jun 2023, 9:59AM Piramal Pharma reports 75% fall in Q4 consolidated net profit25 May 2023, 11:44AM Piramal Pharma - Quaterly Results24 May 2023, 9:49PM

Piramal Pharma Stock Price Analysis and Quick Research Report. Is Piramal Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Piramal Pharma and its performance over the period of time. Piramal Pharma stock price today is Rs 276.8.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Piramal Pharma cash from the operating activity was Rs 358.29 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Piramal Pharma has a Debt to Equity ratio of 0.1723 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Piramal Pharma , the EPS growth was 419.9015 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Piramal Pharma has OPM of 13.6534164292011 % which is a bad sign for profitability.
     
  • ROE: Piramal Pharma have a poor ROE of 6.5496 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Piramal Pharma is Rs 276.8. One can use valuation calculators of ticker to know if Piramal Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Piramal Pharma
X